SERTRALINE HCL MARKET ANALYSIS

Sertraline Hcl MarketSize and Trends

The global sertraline HCl market is estimated to be valued at US$ 1,385.9 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).

Figure 1. Global Sertraline HCl Market Share (%) in Terms of Value, By Application, 2022

Global Sertraline HCl Market: Drivers

Increase in the prevalence of mental disorders is expected to drive the global sertraline HCl market growth over the forecast period. For instance, according to data published by National Institute of Mental Health in January 2022, an estimated 21.0 million adults in the U.S. had at least one major depressive episode in 2020. This number represented 8.4% of all the U.S. adults in 2020.

Increasing product launches for sertraline HCl which is expected to drive the global sertraline HCl market growth during the forecast period. For instance, in November 2021, Camber Pharmaceuticals, a fully integrated international pharmaceutical company, announced that it had added sertraline hydrochloride tablets to their current portfolio, which is the generic version of Zoloft.  Zoloft is an antidepressant that belongs to a group of drugs called selective serotonin reuptake inhibitors (SSRIs), Zoloft is used to treat some types of depression, premenstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), panic disorder (PD), and post traumatic stress disorder (PTSD).

Figure 2. Global Sertraline HCl Market Share (%), By Distribution Channel, 2022

Global Sertraline HCl Market: Restraint

The major factors that hinder growth of the global sertraline HCl market include product recall. For instance, in January 2018, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, is recalling 30-count bottles of 25-mg Zoloft (sertraline hydrochloride) tablets, according to the January 10, 2018, U.S. Food and Drug Administration (FDA) Enforcement report. The company cited weight variations in the tablets that have caused superpotent and subpotent drugs.